AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 31 min read$BDX

Polen Thomas E Jr sold (to issuer) $2.5M of BDX

Polen Thomas E Jr (Chairman, CEO and President) sold (to issuer) 17,445 shares of BECTON DICKINSON & CO (BDX) at $146.15 ($2.55M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Polen Thomas E Jr
Published Jun 3, 2026, 4:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BDX
Neutral
medium confidence
Mentioned
$BDX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

Because the transaction is pre-arranged and disclosed after the fact, it is unlikely to change valuation drivers; it mainly updates insider activity records.

02

Market read

A disclosed insider sale under a 10b5-1 plan typically has limited trading impact absent other catalysts.

03

What to watch

“Sale to issuer” can be tied to routine corporate actions (e.g., buyback mechanics) and may not reflect a directional view; compare with prior insider patterns and total net insider activity.

Relevance 6/10Novelty 2/10Timing: Filed June 3, covering a June 1 insider sale under a 10b5-1 plan.

Background

SEC Form 4 insider transaction: BDX officer/director Polen Thomas E Jr sold 17,445 shares at $146.15 on June 1, 2026 under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$BDXNeutralMedium confidence
Context

Becton Dickinson CEO/Chairman sold $2.55M of BDX shares to the issuer under a pre-arranged 10b5-1 plan, disclosed via Form 4.

Expected impact

Likely limited near-term impact; any reaction is more sentiment/flow-driven than fundamentals.

Evidence & confidence

The filing specifies a pre-arranged 10b5-1 plan and a sale to the issuer (often buyback-related), which reduces interpretive signal versus discretionary selling.

Market effects

Sector

Minimal; this is company-specific insider transaction disclosure without sector-wide read-through.

Regional

Minimal; no geographic or macro linkage indicated.

Global

Minimal; no international deal/regulatory action mentioned.

Counterpoint

What could challenge this read

Treat the sale as a potential signal of reduced near-term confidence, even if 10b5-1 reduces the strength of that inference.

Key entities

  • issuer
    Becton Dickinson & Co

    BDX officer/director insider transaction disclosed on SEC Form 4.

  • insider
    Polen Thomas E Jr

    Chairman, CEO and President; sold shares to the issuer under 10b5-1.

Read at source← All news

Related articles

AUG 8
$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

raps.org7 min
AUG 6
$BDXMed

Becton, Dickinson Boosts FY26 Adj. EPS Outlook - Update

Becton, Dickinson and Co. (BDX) reported third-quarter results and raised its FY2026 adjusted EPS outlook to $12.62 to $12.72 per share, from $12.52 to $12.72. The company kept its revenue growth view, expecting low single-digit plus growth and low single-digit constant-currency growth. Shares were about $172.00 premarket.

rttnews.com2 min
AUG 6
$BDXMedAI 8/10

BD Reports Third Quarter Fiscal 2026 Financial Results

BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.

prnewswire.com6 min